Why now

This is timely and stronger than filler because Ionis announced FDA approval on June 24 for Tryngolza in severe hypertriglyceridemia, specifically to reduce triglycerides and acute pancreatitis risk. The patient-facing angle is prevention of a dangerous complication, not generic lipid optimization. It also has business/platform relevance because this is Ionis' first independent commercial launch in a prevalent condition.

Why now

This is one of the cleanest regulatory items in the batch because FDA posted a June 24 approval for Trodelvy in two first-line adult TNBC indications. The why-now is immediate patient relevance in an aggressive subtype: an antibody-drug conjugate moved earlier in the treatment sequence, including monotherapy for patients not candidates for PD-1/PD-L1 therapy and combination use with pembrolizumab for PD-L1 positive disease. The hook is earlier-line access, not cure.

Why now

Full approval plus expansion to eligible patients age 12 and older makes this more than a routine label update for a rare cancer with limited options.